Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Test-Run Procognia’s Protein Arrays for Kinase-Screening Studies

NEW YORK (GenomeWeb News) – Procognia said today that GlaxoSmithKline will use its protein arrays to profile kinase kits in drug development research.
 
Under the agreement, GSK will use Procognia’s protein array technology with its own kinase inhibitors in profiling studies to assess whether it can integrate these arrays into its screening process.
 
GSK will have use of “over 300 functional kinases,” Procognia said. The Maidenhead, UK-based company said it hopes to “have a functional human protein array containing the entire human kinome” in the second quarter of this year.
 
Procognia also said its protein arrays are used for biomarker discovery, protein interaction, and in identifying substrates.
 
Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.